Rotting Jaw (Jaw Necrosis): Causes, Signs, and Treatment

Jaw necrosis, sometimes called “rotting jaw,” is the death of bone tissue in the upper or lower jaw, most commonly triggered by certain medications or by radiation therapy to the head and neck. The condition ranges from a small patch of exposed bone that aches and refuses to heal to severe destruction that can fracture the jaw itself. Though uncommon, jaw necrosis is painful, difficult to treat once advanced, and surprisingly tied to drugs that millions of people take for osteoporosis and cancer-related bone loss.

What Causes Bone in the Jaw to Die

Jaw necrosis falls into a few broad categories based on cause. The most talked-about form today is medication-related osteonecrosis of the jaw, shortened to MRONJ. Two drug classes are responsible for nearly all cases. Bisphosphonates, widely prescribed for osteoporosis and to prevent bone damage from cancers like multiple myeloma, work by binding to bone mineral and shutting down the cells that normally break down and recycle old bone. Denosumab, a newer injectable drug, achieves a similar result through a different route: it blocks a signaling molecule called RANKL that osteoclasts (the bone-recycling cells) need to develop and survive.¹ Both drugs are effective at strengthening bone elsewhere in the body, but they leave the jaw uniquely vulnerable because jaw bone turns over faster than bone in the hip or spine, and the thin tissue lining the mouth offers less protection from bacteria and trauma.

The second major cause is radiation therapy aimed at head and neck cancers. Osteoradionecrosis, or ORN, develops when radiation damages the blood vessels and cells inside the jaw bone. An older theory blamed oxygen starvation in irradiated tissue, but more recent research points to radiation-induced fibrosis: an ongoing cycle of inflammation, free-radical damage, and abnormal activation of connective-tissue cells that slowly chokes off the bone’s ability to repair itself.² ORN is typically defined as exposed jaw bone that fails to heal for at least three months after radiation ends, with no sign of tumor recurrence.³

There is also a historical form worth knowing about. In the 1800s, factory workers making friction matches developed a condition called “phossy jaw” after inhaling white phosphorus fumes. They suffered gum disease, loosened teeth, draining sores, and sometimes fractures of the lower jaw. The condition vanished after international bans on white phosphorus in match production took effect in 1906, but the parallels to modern MRONJ are striking enough that researchers still study the comparison.⁴

Why the Jaw and Not Other Bones

People reasonably wonder why drugs that affect the whole skeleton cause problems almost exclusively in the jaw. The answer lies in a combination of factors that converge in the mouth. The jaw bones, especially the lower jaw, have some of the highest rates of bone turnover in the body. They are also the only bones that routinely poke through the body’s surface: the thin layer of gum tissue covering the ridges where teeth sit can be breached by something as routine as chewing, a dental extraction, or even the pressure of a denture. Once that barrier is broken, oral bacteria flood in. In a jaw whose bone-repair machinery has been shut down by bisphosphonates or denosumab, the damage simply cannot heal.

Beyond the impaired recycling of bone cells, research in animal models has identified an additional mechanism: these medications also appear to damage the blood supply to the oral lining and reduce the function of the cells responsible for wound healing in soft tissue.⁵ So it is not just that the bone cannot rebuild; the gum above it cannot close over the wound either. Bacteria from the mouth, particularly Actinomyces species that normally live there harmlessly, then colonize the exposed bone and drive chronic infection deeper.⁶

What Triggers It and Who Is at Higher Risk

Most people who take bisphosphonates or denosumab never develop jaw necrosis. The condition is considered rare, but certain events and underlying health problems raise the odds substantially.

Tooth extraction is the single most recognized trigger. In one study of 652 patients prescribed oral bisphosphonates, the overall rate of jaw necrosis following an extraction was about 0.8 percent. Among those who had been on the drugs for four or more years, the rate doubled to roughly 1.6 percent.⁷ Dental implant placement is another known trigger, and research has confirmed that even the mere presence of an implant already in the bone can be associated with the disease, not only the surgical insertion itself.⁸ Other oral surgeries, poorly fitting dentures, and even spontaneous breakdown of gum tissue have all been reported as starting points.

On the systemic side, patients receiving high-dose intravenous bisphosphonates for cancer (as opposed to the lower oral doses used for osteoporosis) face a much higher risk. Diabetes is an increasingly recognized contributor, likely because it damages small blood vessels, impairs the function of bone-building cells, and slows healing through multiple overlapping pathways.⁹ Corticosteroid use, chemotherapy, and smoking also raise the likelihood.

Signs and Symptoms to Watch For

The hallmark sign is exposed bone in the mouth that persists for more than eight weeks. But jaw necrosis does not always start that dramatically. Early on, you might notice dull, aching jaw pain that does not match any obvious dental problem, loose teeth in an area that was previously stable, numbness or heaviness in the jaw, or gums that look swollen and do not respond to normal treatment. Some patients first notice a foul taste or bad breath that will not go away.

Clinicians classify MRONJ into stages, and the staging matters because it drives treatment decisions. The widely used system from the American Association of Oral and Maxillofacial Surgeons includes a stage 0 for patients who have suggestive symptoms but no visible bone exposure yet.¹⁰ A meaningful percentage of stage-0 patients go on to develop worse disease, which is why clinicians take those vague early symptoms seriously. Stage 1 involves exposed bone without infection. Stage 2 adds pain, infection, and sometimes pus. Stage 3 means the necrosis has spread to cause a fracture, a fistula draining through the skin, or bone loss extending beyond the immediate area.

How It Is Diagnosed

A clinical exam is usually the starting point: a dentist or oral surgeon looks in the mouth for exposed, discolored bone, probes the area, and takes a patient history focused on medication use and radiation treatment. But imaging plays a critical role, especially in early or ambiguous cases.

Standard panoramic X-rays catch advanced disease but miss a lot of early changes. CT scans and cone-beam CT are considerably better, revealing features like periosteal reactions along the bone surface, holes in the outer bone shell, and a distinctive “bone-within-bone” pattern that is characteristic of MRONJ.¹¹ MRI can detect changes in the marrow and surrounding soft tissue that other modalities miss, making it particularly useful for spotting stage-0 or subclinical disease. A review of the evidence found that CT and MRI both vastly outperform panoramic X-rays in early detection, with accuracies around 96 and 92 percent compared to roughly 54 percent for panoramic films.¹² One caveat is that both CT and MRI tend to overestimate how far the necrosis actually extends, which surgeons account for during operations.

Conservative Treatment

Not every case of jaw necrosis needs surgery. For early-stage disease, the first line of treatment is conservative management: antibiotics to control infection, antiseptic mouth rinses, and careful monitoring. A common regimen includes high-dose amoxicillin (or clindamycin for those allergic to penicillin), with metronidazole added in stubborn cases, along with chlorhexidine rinses and gel applied directly to the exposed bone.¹³ Pain control, gentle debridement of loose bone fragments, and sometimes a temporary pause in the offending medication round out the approach.

For stage-2 disease, combining antibiotics and antiseptic rinses with minimally invasive removal of dead bone has shown effectiveness.¹⁴ The goal at this point is to eliminate infection, reduce pain, and prevent progression to a stage where more radical surgery becomes necessary.

When Surgery Becomes Necessary

Stage-3 disease and stage-2 cases that do not respond to conservative care often require surgical resection, meaning removal of the affected section of jaw bone. In many of these patients, surgeons then reconstruct the jaw using a vascularized free flap, a segment of bone with its own blood supply taken from another part of the body such as the leg (fibula) or shoulder blade (scapula). In a review of patients with advanced MRONJ treated this way, all reported resolution of symptoms and achieved complete bone healing on follow-up imaging.¹⁵ This approach has proven effective even in patients with significant vascular disease, which is reassuring given that many of these patients are older or medically complex.¹⁶

These are major operations, however. Removing a section of jaw and rebuilding it with a flap from the leg involves a lengthy surgery, hospital stay, and rehabilitation. Not every patient is a candidate, and the decision to proceed requires balancing the severity of the necrosis against the patient’s overall health and the cancer treatment they may still need.

The Hyperbaric Oxygen Debate

Hyperbaric oxygen therapy, which involves breathing pure oxygen in a pressurized chamber, has been used for decades under the logic that flooding irradiated or necrotic tissue with oxygen might jump-start healing. For osteoradionecrosis specifically, the evidence has been mixed and contentious. A multidisciplinary guideline review at a major cancer center found no consistent evidence supporting hyperbaric oxygen for either preventing or treating ORN.¹⁷ A randomized, placebo-controlled trial found that patients with established mandibular ORN did not benefit from the treatment.¹⁸

That said, combined data from two more recent randomized trials painted a slightly more optimistic picture: about 70 percent of patients receiving hyperbaric oxygen healed compared to 51 percent receiving standard care, and the therapy was associated with improvements in dry mouth and swallowing. But neither trial recruited enough patients to reach statistical significance on its endpoints.¹⁹ So the honest state of affairs is that hyperbaric oxygen remains unproven as a standalone treatment for jaw necrosis, even if some data hints it might help in certain patients.

Platelet-Rich Fibrin and Other Emerging Approaches

One of the more promising newer strategies uses the patient’s own blood products to accelerate healing. Platelet-rich fibrin (PRF) is prepared by drawing a small amount of blood, concentrating the platelets and growth factors, and applying the resulting membrane directly to the surgical wound. In one study, PRF treatment reduced symptoms and signs in about 83 percent of cases, compared to roughly 65 to 71 percent with conventional wound closure methods.²⁰

Results appear to improve further when PRF is combined with bone morphogenetic protein-2, a growth factor that stimulates new bone formation. Patients treated with both PRF and BMP-2 showed complete resolution of their lesions at 16 weeks, a result that was statistically significant compared to PRF alone.²¹ These are still relatively small studies, but the direction of the evidence is encouraging enough that many oral surgery centers have begun incorporating PRF into their treatment protocols for MRONJ.²²

Prevention Before It Starts

The single most effective intervention for jaw necrosis is preventing it. Evidence consistently supports a straightforward strategy: get a thorough dental evaluation and complete any necessary dental work before starting bisphosphonates, denosumab, or head-and-neck radiation.²³ That means extracting hopeless teeth, treating gum disease, and addressing any infections before the medication or radiation begins, so that the mouth is as healthy as possible going in.

During and after treatment, ongoing dental monitoring matters. A single-center study found that comprehensive dental care provided before starting antiresorptive or antiangiogenic drugs was a potentially effective way to reduce MRONJ.²⁴ In practice, that means telling every dentist and oral surgeon about any bone-related medications you take or have taken, keeping up with regular cleanings, and flagging any unusual mouth symptoms early rather than waiting.

For patients already on these drugs who need a tooth extracted, the situation is trickier. Some clinicians advocate a “drug holiday,” temporarily pausing the medication around the time of the procedure. Whether this actually reduces risk is debated, and pausing treatment introduces its own risks (fractures, cancer progression) that need to be weighed against the relatively low probability of jaw necrosis.

How Jaw Necrosis Affects Daily Life

The physical toll of jaw necrosis is obvious: pain, difficulty eating, infection, and sometimes disfigurement. But the psychological and social effects often go underappreciated. In a study measuring quality of life across the stages, patients with advanced (stage 3) disease reported dramatically lower well-being scores than those without jaw necrosis. Pain, discomfort while eating, self-consciousness about appearance, interrupted meals, irritability, and decreased overall life satisfaction all increased significantly as the disease worsened. Anxiety and depression were among the biggest contributors to declining quality of life.²⁵

A systematic review confirmed that jaw necrosis negatively affects quality of life among both cancer patients and those treated for osteoporosis.²⁶ Eating and socializing become fraught when your mouth hurts, smells, or has visible exposed bone. Patients sometimes withdraw from meals with family or avoid speaking in public. These impacts are worth discussing openly with a care team, because pain management, nutritional support, and mental health resources can all make a real difference even while the underlying condition is being treated.

Jaw Necrosis in Children

Bisphosphonates and denosumab are increasingly used in children for conditions like aggressive bone tumors and secondary osteoporosis. Naturally, parents worry about whether their child faces the same jaw necrosis risk as adults. A study examining 178 pediatric patients (average age about 12) treated with these drugs found zero cases of jaw necrosis across the entire group.²⁷ The most common reason for treatment was adjuvant therapy for aggressive tumors, followed by osteoporosis. While dental care before starting treatment is still recommended, the data suggest that the risk in children is very low, possibly because children’s jaw bone turns over so rapidly that the drug-related suppression does not accumulate the way it does in adults over years of use.

Jaw Necrosis in Dogs and Other Animals

Veterinarians have documented jaw necrosis in dogs that closely resembles the human condition, which is part of why dogs are used as research models. Dogs have a bone remodeling rate similar to humans, and experimental models of MRONJ using months to years of bisphosphonate treatment in dogs have produced mandibular necrosis.²⁸ In naturally occurring cases, histological examination of dog jaws shows dead bone with empty cell spaces and heavy inflammation, consistent with chronic bone infection.²⁹ Most intriguing, some dogs develop what researchers call idiopathic jaw necrosis, meaning no clear drug or radiation trigger can be identified, and investigations are underway to understand whether similar risk factors and co-occurring conditions apply across species.³⁰ At least one case has also been documented in a cat after prolonged bisphosphonate use, suggesting the phenomenon is not limited to any single species.